Manuel Nicolás
Hernández Guerra de Aguilar
Profesor Titular Universidad
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (27)
2023
-
Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration
Hepatology, Vol. 77, Núm. 4, pp. 1095-1105
-
Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction
Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 150-162
2022
-
Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study
Alimentary Pharmacology and Therapeutics, Vol. 56, Núm. 1, pp. 131-143
2021
-
Carotid plaque assessment reclassifies patients with inflammatory bowel disease into very-high cardiovascular risk
Journal of Clinical Medicine, Vol. 10, Núm. 8
-
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects
Liver International, Vol. 41, Núm. 9, pp. 2076-2086
-
Insulin resistance is not increased in inflammatory bowel disease patients but is related to non-alcoholic fatty liver disease
Journal of Clinical Medicine, Vol. 10, Núm. 14
-
Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review
Scientific Reports, Vol. 11, Núm. 1
-
Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study
American Journal of Gastroenterology, Vol. 116, Núm. 11, pp. 2250-2257
-
Qrisk3 performance in the assessment of cardiovascular risk in patients with inflammatory bowel disease
Journal of Clinical Medicine, Vol. 10, Núm. 18
2020
-
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure
Antiviral Research, Vol. 174
-
Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))
Journal of Hepatology
-
International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis
Liver International, Vol. 40, Núm. 6, pp. 1467-1476
2019
-
Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH
Gastroenterologia y Hepatologia, Vol. 42, Núm. 10, pp. 657-676
-
Chronic kidney disease staging with cystatin C or creatinine-based formulas: Flipping the coin
Nephrology Dialysis Transplantation, Vol. 34, Núm. 2, pp. 287-294
-
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs
Journal of Hepatology, Vol. 71, Núm. 4, pp. 666-672
-
Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)
Gastroenterologia y Hepatologia, Vol. 42, Núm. 9, pp. 579-592
-
Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain
PLoS ONE, Vol. 14, Núm. 11
2018
-
Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events
Hepatology, Vol. 67, Núm. 2, pp. 612-622
-
Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline
Gastroenterologia y Hepatologia, Vol. 41, Núm. 5, pp. 328-349
-
Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349] (S0210570518300037) (10.1016/j.gastrohep.2017.12.003))
Gastroenterologia y Hepatologia